VRTX Vertex Pharmaceuticals Inc / Ma stock chart & analysis
Conviction 49HealthcareScan · Fri, Nov 6, 2026Vertex Pharmaceuticals Inc / Ma (VRTX) closed at $547.09 (+0.85%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 58, RS Rating 87, -3.8% from its 52-week high, +20.6% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
VRTX technical analysis
Trend
VRTX is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 4.6% above the 50-day ($522.79) and 13.6% above the 200-day ($481.57). ADX(14) at 17 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 58, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 87 puts its weighted 12-month performance ahead of about 87% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $876.6M a day on average. ATR(14) is $17.41, 3.2% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.06) shows distribution.
Key levels
The chart pattern's support is $490.12 and its resistance $553.24. The 52-week range is $406.67 to $568.67; price is 3.8% below the high and 34.5% above the low. The VWAP anchored at the 52-week high is $546.90, below price.
Performance
VRTX returned -2.1% (1 week), +8.7% (1 month), +4.4% (3 months), +27.2% (6 months), +31.1% (1 year), +20.6% (year to date).
About Vertex Pharmaceuticals Inc / Ma
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Pharmaceutical Preparations · Listed 1991 · 6,400 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 31 – Oct 144 scans
- Breaking out nowOct 151 scan
- Setting upOct 161 scan
Congress activity
Disclosed STOCK Act trades in VRTX · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 David J. Taylor house · R · OH · traded 2026-08-26 | Sell | $1K–$15K | 2026-08-26 | 2026-09-05 | |
 Thomas H Tuberville senate · traded 2024-05-03 | Sell | $1K–$15K | 2024-05-03 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
David J. Taylor house · R · OH · traded 2025-08-07 | Buy | $1K–$15K | 2025-08-07 | 2025-09-02 | |
 Lisa McClain house · R · MI · traded 2024-12-11 | Buy | $1K–$15K | 2024-12-11 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-11 | Sell | $1K–$15K | 2025-06-11 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-10 | Sell | $1K–$15K | 2025-06-10 | 2025-08-13 | |
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $15K–$50K | 2025-05-12 | 2025-06-22 | |
 Byron Donalds house · R · FL · traded 2025-03-20 | Sell | $1K–$15K | 2025-03-20 | 2025-04-14 | |
Jefferson Shreve house · R · IN · traded 2025-03-13 | Buy | $15K–$50K | 2025-03-13 | 2025-04-11 |
Insider activity
SEC Form 4 transactions in VRTX · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
SACHS BRUCE I Director · Deferred Stock Units · 2026-10-15 | Grant | 92.694 | $48K | 2026-10-15 | 2026-10-19 |
Garber Alan M Director · Deferred Stock Units · 2026-10-15 | Grant | 29.272 | $15K | 2026-10-15 | 2026-10-19 |
Ambrose Kristen SVP & Chief Accounting Officer · Common Stock · 2026-08-28 | Grant | 5K | — | 2026-08-28 | 2026-09-01 |
SACHS BRUCE I Director · Common Stock · 2026-08-27 | Gift | 6K | — | 2026-08-27 | 2026-08-31 |
SACHS BRUCE I Director · Deferred Stock Units · 2026-07-15 | Grant | 99.941 | $47K | 2026-07-15 | 2026-07-17 |
Garber Alan M Director · Deferred Stock Units · 2026-07-15 | Grant | 31.56 | $15K | 2026-07-15 | 2026-07-17 |
Tatsis Ourania EVP, Chief Reg. & Quality Off. · Common Stock · 2026-07-02 | Sell | 1.5K | $787K | 2026-07-02 | 2026-07-07 |
McKechnie Duncan EVP, Chief Commercial Officer · Common Stock · 2026-07-02 | Sell | 1.54K | $800K | 2026-07-02 | 2026-07-07 |
Bozic Carmen EVP and CMO · Common Stock · 2026-06-26 | Sell | 596 | $288K | 2026-06-26 | 2026-06-30 |
Bozic Carmen EVP and CMO · Common Stock · 2026-06-15 | Sell | 4.06K | $1.8M | 2026-06-15 | 2026-06-17 |
SEC filings
EDGAR filings in VRTX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.